Anchyra Partners’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
Other funds holding VRTX
Anchyra Partners's VRTX Position: Q3 2026 in Review
Anchyra Partners increased its Vertex Pharmaceuticals (VRTX) stake by 19% in Q3 2026, buying an estimated $61.4K and bringing the position to 740 shares worth $387K. The position accounts for 0.08% of the portfolio, ranked #219.
Anchyra Partners first reported a position in VRTX in Q4 2025 and has held it in 4 quarters since. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.
- Anchyra Partners held 740 shares of Vertex Pharmaceuticals worth $387K as of Q3 2026.
- Anchyra Partners bought 120 Vertex Pharmaceuticals shares in Q3 2026, an estimated $61.4K.
- Vertex Pharmaceuticals made up 0.08% of Anchyra Partners's portfolio in Q3 2026, its #219 holding.
- Anchyra Partners first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
- 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.
Based on Anchyra Partners's 13F filing for Q3 2026, filed 13 Oct 2026.